Reliance Pharma Fund Bonus-0.97%

5Groww
-14.11%
1 Year Return
Equity
Sectoral/Thematic
5.0 star
6M
1Y
3Y
5Y
All

Fund Details

Reliance Pharma Fund Bonus

RiskHigh
Min SIP AmountNot Supported
Expense Ratio2.17%
NAV140.17 (19 Sep 2019)
Fund Started05 Jun 2004
Fund Size2,377 Cr

Returns

1Y
3Y*
5Y*
Since inception*
Reliance Pharma Fund Bonus
-14.1%
-1.5%
3.4%
18.8%
Category Average
-5.2%
-4.5%
3.9%
-
Rank within category
3
1
1
-
*All returns are annualized.
SIP
Lumpsum
I want to invest per month5,000
    For how many years?
    1 Year
    3 Years
    5 Years
    Estimated Value
    as per Historical Returns
    30
    with -14.1% annual returns

    Comparison

    Data not available
    Pros
    1. Age is more than 10 years
    2. Risk is lower compared to the benchmark
    3. 1Y Returns are higher than the benchmark
    4. 3Y Returns are higher than the benchmark
    5. 5Y Returns are higher than the benchmark
    6. 10Y Returns are higher than the benchmark
    Cons
    1. Risk-adjusted returns are lower compared to the category
    2. Higher expense ratio

    Top Holdings

    NameSectorInstrument% Assets
    Sun Pharmaceutical Inds. Ltd.HealthcareEquity12.3%
    Divi's Laboratories Ltd.HealthcareEquity10.3%
    Cipla Ltd.HealthcareEquity8.6%
    Aurobindo Pharma Ltd.HealthcareEquity8.3%
    Lupin Ltd.HealthcareEquity7.2%
    Dr. Reddy's Laboratories Ltd.HealthcareEquity7.0%
    Abbott India Ltd.HealthcareEquity6.8%
    Syngene International Ltd.HealthcareEquity6.5%
    Fortis Healthcare (India) LtdHealthcareEquity6.0%
    Sanofi India Ltd.HealthcareEquity5.8%
    See All

    Fund Managers

    addSailesh Raj Bhan
    Education
    Mr. Bhan is an MBA (Finance) and CFA.
    Experience
    Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.
    Funds Managed

    Other Details

    Reliance Pharma Fund Bonus is a Equity Mutual Fund Scheme launched by Reliance Mutual Fund. This scheme was introduced to investors on 05 Jun 2004. Sailesh Raj Bhan is the Current Fund Manager of Reliance Pharma Fund Bonus.The fund currently has an Asset Under Management(AUM) of ₹2,377 Cr and the Latest NAV as of 19 Sep 2019 is ₹140.17.

    The Reliance Pharma Fund Bonus is rated High risk. Minimum SIP Investment is 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.

    Investment Objective

    To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.

    Tax Implications

    Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.

    Scheme Information Document(SID)

    ₹5000
    Min for First Investment
    ₹1000
    Min for Second Investment
    Exit load of 1% if redeemed within 1 year
    Exit Load

    Compare Funds

    Reliance Pharma Fund Bonus
    VS
    search

    About Reliance Mutual Fund

    Address
    Corporate Office : Reliance Centre, 7th Floor South Wing, OFf Western Express Highway, Santacruz(E) Mumbai-400055
    Phone
    022-33031000/30301111
    Launch Date
    29 Jun 1995
    Reliance Mutual Fund
    Asset Management Company
    Custodian
    ABN AMRO Bank
    Registrar & Transfer Agent
    Karvy
    Address
    Karvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,
    Invest Now
    Enter investment amount
    + ₹1,000
    + ₹5,000
    + ₹10,000
    ONE TIME
    MONTHLY SIP
    Similar Funds
    Data not available